Two-year results of the TRILUMINATE pivotal trial demonstrate a sustained benefit of tricuspid transcatheter edge-to-edge repair (T-TEER) for the treatment of severe tricuspid regurgitation
“We’ve referred to this as the forgotten valve,” Gagan Singh (UC Davis Health, Sacramento, USA), an investigator in the trial, tells Cardiovascular News, referencing the fact that solutions for the treatment of tricuspid valve disease have often lagged behind other areas of structural heart disease—though with new data entering the field, this is picture is now changing.
Singh shares insights from the pivotal trial, including what the study has been able to show on the natural history of tricuspid valve disease, and how the findings could influence future treatment choices for interventionalists.
